Clinical trials: Hepatitis C Infections
Hepatitis C Virus Infection
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks compared to treatment with sofosbuvir (SOF)…
- Trial name
- ASTRAL-2 (NCT02220998)
- Testing
- SOF/VEL, SOF, RBV
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 269 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C
This study seeks to provide evidence of the effectiveness and obtain patient reported outcomes (PRO) and work productivity data of the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), +/- dasabuvir…
- Trial name
- NCT02640547
- Volunteers
- 394 people
- Sponsor
- AbbVie
Hepatitis C Infection With HIV Co-Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with acute genotype 1 or 4 hepatitis C virus (HCV)…
- Trial name
- NCT02457611
- Testing
- LDV/SOF
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences
Hepatitis, Hepatitis C
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
The primary objective for this study is to determine if the addition of filibuvir to a standard regimen of peginterferon/ribavirin (pegIFN/RBV) significantly increases the proportion of subjects who achieve a sustained viral…
- Trial name
- FITNESS (NCT00987337)
- Testing
- Filibuvir
- Where
- 77 sites in United States, Belgium and 7 more
- Volunteers
- 288 people
- Sponsor
- Pfizer
Hepatitis C Virus Infection
Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection
This study will have 2 parts: Pharmacokinetics (PK) Lead-in Phase and the Treatment Phase. The primary objective of the PK Lead-in Phase is to evaluate the steady state PK and confirm the dose of sofosbuvir/velpatasvir (SOF/VEL)…
- Trial name
- NCT03022981
- Testing
- SOF/VEL
- Where
- 27 sites in United States, Belgium and 2 more
- Volunteers
- 216 people
- Sponsor
- Gilead Sciences
Hepatitis C
An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria
This noninterventional, open-label study will observe the safety and tolerability of peginterferon alfa-2a in combination with ribavirin among Austrian participants treated for HCV infection according to routine practice.
- Trial name
- NCT02515279
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- Austria
- Volunteers
- 463 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Infection
A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir (SOF) and ribavirin (RBV) in DAA treatment-experienced adults with Genotype 1 Chronic…
- Trial name
- NCT02356562
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, Sofosbuvir, Ribavirin
- Volunteers
- 29 people
- Sponsor
- AbbVie
HCV
TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers
The purpose of this study is to evaluate the safety and tolerability of three different doses of TMC435350 compared to placebo in healthy Japanese males.
- Trial name
- NCT00752544
- Testing
- TMC435350
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C Virus
TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435
The purpose of this study is to assess the steady-state pharmacokinetics of TMC435 in participants with severe renal impairment and to compare these with the TMC435 pharmacokinetics in matched participants with normal renal…
- Trial name
- NCT01381835
- Testing
- TMC435
- Where
- Czechia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Chronic Hepatitis C Infection
Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
The primary objective of this protocol is to study the effect of the standard of care in hepatitis C (pegylated interferon and ribavirin) associated with therapeutic vaccine TG4040 on the viral load of treatment-naïve patients…
- Trial name
- HCVac (NCT01055821)
- Testing
- pegylated interferon and ribavirin, TG4040 + SOC
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- Transgene
Hepatitis, Chronic Active
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
The purpose of this study is to determine the efficacy and tolerability of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RBV) compared to PEG-IFN and RBV without CPG 10101 in…
- Trial name
- NCT00277238
- Testing
- CPG10101, Control
- Where
- 14 sites in United States
- Volunteers
- 113 people
- Sponsor
- Pfizer
Hepatitis C Viral Infection, Chronic Hepatitis C
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
Phase 2a study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 in combination with Ribavirin for a 12-week treatment duration in treatment-naïve participants with genotype 4 hepatitis C…
- Conditions
- Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 4
- Trial name
- NCT02593162
- Testing
- Faldaprevir, TD-6450, Ribavirin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Trek Therapeutics, PBC
Hepatitis C, Chronic
Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection
Primary objectives: The purpose of this study is to determine and compare the sustained virologic response (SVR, undetectable HCV RNA at Follow up week 24 (FW24)) across treatment groups.
- Trial name
- NCT01587586
- Testing
- PEGASYS 180 µg Q1W, P1101 180 µg Q1W, 48 doses, P1101 270µg Q1W, 48 doses
- Where
- 13 sites in Taiwan
- Volunteers
- 107 people
- Sponsor
- PharmaEssentia
Chronic Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
The purpose of this study is to evaluate the safety and efficacy of a quadruple regimen (VX-222, telaprevir, pegylated interferon, and ribavirin)in subjects with hepatitis C with cirrhosis.
- Trial name
- NCT01516918
- Testing
- VX-222, telaprevir, ribavirin
- Where
- 43 sites in United States, Canada and 3 more
- Volunteers
- 103 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Hepatocellular Carcinoma
Direct Acting Antiviral-Post Authorization Safety Study
This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting…
- Trial name
- NCT03707080
- Where
- 62 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Target PharmaSolutions, Inc.
Hepatitis C, Hepatitis C, Chronic
Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)
The objective of this study is to determine the relapse rate in the French patient population with chronic hepatitis C (CHC) previously treated with PegInterferon Alfa-2b (Peg-IFN alfa-2b) plus Ribavirin according to standard…
- Trial name
- RE-CHUT (NCT00725842)
- Testing
- Peg-IFN alfa-2b, Ribavirin
- Volunteers
- 97 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
This use-results post-marketing surveillance (PMS) study for Sovaldi® tablets (sofosbuvir, SOF) administered in combination with Rebetol® capsules (ribavirin, REB) will evaluate the safety and efficacy of SOF administered in…
- Trial name
- NCT02562742
- Testing
- SOF, REB
- Where
- 45 sites in Japan
- Volunteers
- 554 people
- Sponsor
- Gilead Sciences
Diphtheria, Tetanus
Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants
To compare three formulations of Hib-MenAC vaccines mixed with Tritanrix™-HepB vaccine with that of Tritanrix™-HepB vaccine concomitantly administered with GSK Biologicals' Hiberix™ vaccine and Tritanrix™-HepB vaccine mixed with…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00291967
- Testing
- DTPw-HBV/Hib-MenAC conjugate vaccine
- Where
- Philippines
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic
The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Primary Objective: To determine the P1101 pharmacokinetic (PK) profile at the single dose of 400 μg.
- Trial name
- NCT04774107
- Testing
- P1101 + Ribavirin
- Where
- 5 sites in Taiwan
- Volunteers
- 17 people
- Sponsor
- PharmaEssentia
Hepatitis C
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.
- Trial name
- NCT00621296
- Testing
- MP-424 (Telaprevir)
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Tanabe Pharma Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.